ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ONCO vs GRI // FREE CASH FLOW YIELD

Onconetix Inc. (NASDAQ) VS. GRI Bio Inc. (NASDAQ) • 15-METRIC TALLY: ONCO 3 — GRI 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONCO VS. GRI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ONCO GRI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 77.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ONCO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.8 46.1 +4.70 ONCO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.5M $3.4M $25.2K ONCO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ONCO REV GRI REV ONCO GROSS % GRI GROSS % ONCO FCF GRI FCF
FY 2025 $815.4K $0 77.6% — -$9.7M -$10.2M
FY 2024 $2.5M $0 41.8% — -$10.5M -$8.6M
FY 2023 $58.5K $0 — — -$13.6M -$9.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONCO // BETA —
GRI // BETA —